


 Enge

1646

TRANSMITTAL FORM (To be used for all correspondence after initial filing)	Application Number	09/912,674
	Filing Date	July 20, 2001
	First Named Inventor	Donald S. Karanewsky
	Art Unit	1646
	Examiner Name	
	Attorney Docket No.	480140.444C1

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement; Form PTO-1449 <input checked="" type="checkbox"/> 7 Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (<i>Appeal Notice, Brief, Reply Brief</i>) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (<i>please identify below</i>): _____ _____ _____
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Individual Name	Emily W. Wagner Reg. No. 50,922	Customer Number 00500
Signature		
Date	April 13, 2004	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Lawrence Teague	
Signature		Date: April 13, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 1473837



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

April 13, 2004
Date

Lawrence Teague
Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Donald S. Karanewsky et al.
Application No. : 09/912,674
Filed : July 20, 2001
For : (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE
ICE/ced-3 FAMILY OF CYSTEINE PROTEASES

Art Unit : 1646
Docket No. : 480140.444C1
Date : April 13, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware


of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Emily W. Wagner

Registration No. 50,922

EWV:ljt

Enclosures:

Postcard
Transmittal Form
Form PTO-1449
Cited References (7)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

\473845

APR 16 2004

Sheet 1 of 1

FORM PTO-449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

480140.444C1

09/912,674

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)

APPLICANTS

Donal S. Karanewsky et al.

FILING DATE

July 20, 2001

GROUP ART UNIT

1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,585,357	12/17/96	Dolle et al.	514	18	
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AF					
	AG					
	AH					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AI	Brennan, F.M et al., "Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures," <i>Clinical and Experimental Immunology</i> 81: 278-285, 1990.
	AJ	Frost, R.A. et al., "Lipopolysaccharide regulates proinflammatory cytokine expression in mouse myoblasts and skeletal muscle," <i>Am. J. Physiol. Regul. Interg. Comp. Physiol.</i> 283: R698-R709, September 2002.
	AK	Meyers, K.P. et al., "Effect of Treatment with Interleukin-1 Receptor Antagonist on the Development of Carrageenan-Induced Pleurisy in the Rat," <i>Inflammation</i> 17(2): 121-134, April 1993.
	AL	París, M.M. et al., "Effect of Interleukin-1 Receptor Antagonist and Soluble Tumor Necrosis Factor Receptor in Animal Models of Infection," <i>The Journal of Infectious Diseases</i> 171(1): 161-169, January 1995.
	AM	Read, S.J. et al., "Limiting Neurological Damage After Stroke. A Review of Pharmacological Treatment Options," <i>Drugs & Aging</i> 14(1): 11-39, January 1999.
	AN	Rosenbaum and Boney, "Activity of an Interleukin 1 Receptor Antagonist in Rabbit Models of Uveitis," <i>Archives of Ophthalmology</i> 110: 547-549, April 1992.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).